Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Certolizumab pegol

Certolizumab Pegol Drug Studies Find No New Safety Issues

Michele B. Kaufman, PharmD, BCGP  |  March 1, 2015

Plus, updates on clazakizumab, hydrocodone bitartrate extended-release capsules and other rheumatology drug news, safety information

Filed under:Drug Updates Tagged with:Certolizumab PegolclazakizumabdrugFDAhydrocodone bitartrateKaufmanrheumatologySafety

Clinical Criteria for RA & Early Non-Response to Certolizumab as Predictors of Patient Outcomes

Lara C. Pullen, PhD  |  May 25, 2020

A recent study compared three clinical criteria for rheumatoid arthritis (RA) in patients using certolizumab, assessing the predictability of treatment non-response. Researchers found Clinical Disease Activity Index measurement at three months may predict patient outcomes at 12 months…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Certolizumab PegolOutcomesRheumatoid Arthritis (RA)

Transfer of Certolizumab in Breast Milk Not a Concern

Reuters Staff  |  November 22, 2016

NEW YORK (Reuters Health)—There is minimal to no transfer of the tumor necrosis factor (TNF) inhibitor certolizumab (Cimzia) from plasma to breast milk, according to a new study. “These findings are reassuring” and imply that continuing certolizumab treatment is compatible with breastfeeding, Dr. Megan Clowse of Duke University School of Medicine in Durham, North Carolina,…

Filed under:Drug Updates Tagged with:breast milkCertolizumab PegolTNFTNF inhibitor

Certolizumab Combo Helps Curb RA Damage

David Douglas  |  June 15, 2016

NEW YORK (Reuters Health)—Certolizumab pegol (Cimzia, UCB Pharma) in combination with methotrexate does better than methotrexate alone in certain patients with early rheumatoid arthritis (RA), according to one-year results from a new trial. As Dr. Paul Emery of the University of Leeds, UK, explains in an email to Reuters Health, “This study used a unique…

Filed under:Drug Updates Tagged with:Certolizumab Pegolcombination therapyDisease-modifying antirheumatic drugs (DMARDs)MethotrexateRheumatoid Arthritis (RA)

New RA Therapy Promising in Clinical Trial

Michele B. Kaufman, PharmD, BCGP  |  August 3, 2016

Results from a clinical trial support the efficacy of vobarilizumab for treating RA. Plus, the UK will recommend the use of certolizumab pegol to treat severe cases of RA in upcoming guidelines…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Certolizumab PegolInternationalRheumatoid Arthritis (RA)tocilizumabvobarilizumab

Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA

Michele B. Kaufman, PharmD, BCGP  |  December 25, 2015

In clinical trials, ixekizumab and adalimumab proved safe and effective in treating adults with active psoriatic arthritis. Also, the combination therapy of certolizumab pegol plus methotrexate was more effective than placebo for treating severe RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumabBiologicsCertolizumab Pegolcombination therapyixekizumabMethotrexatePsoriatic ArthritisRheumatoid Arthritis (RA)

3 AC&R Study Summaries: Maternal Health & SLE, Pregnancy Outcomes & Coordinated Ophthalmic & Rheumatologic Care

Arthritis Care & Research  |  February 7, 2025

Maternal Health Insights in Patients with SLE The impact of pregnancy readiness on lupus activity, maternal mental health & pregnancy outcomes By Ceshae Harding, MD, & Megan Clowse, MD, MPH Why was this study done? Patients with systemic lupus erythematosus (SLE) who are pregnant have increased risks of risks maternal and fetal mortality, preeclampsia and…

Filed under:ConditionsResearch ReviewsResearch RheumRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:AC&RopthalmologistpregnancyReading RheumUveitis

FDA Officials Discuss Extrapolation & Confusion Around Pediatric Therapies

Thomas R. Collins  |  December 3, 2024

A session at ACR Convergence 2024 addressed several recent drug approvals in pediatric rheumatology and a safety update for IL-1/IL-6 inhibitors.

Filed under:ACR ConvergenceDrug UpdatesPediatric Conditions Tagged with:ACR Convergence 2024Biosimilarsdrug approvalsinterchangeabilityPediatric RheumatologyU.S. Food and Drug Administration (FDA)

Where Are We with RA? Prevention, Treatment & Management Challenges

Samantha C. Shapiro, MD  |  December 3, 2024

In this Review Course at ACR Convergence 2024, Iain McInnes, PhD, FRCP, discussed some of the challenges of RA: Remission is drug maintained, multimorbidity abounds, treatment strategies can be complex, & prevention is not yet possible.

Filed under:ACR ConvergenceConditionsRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 RA

Clinical Year in Review: 2023

Samantha C. Shapiro, MD  |  December 4, 2023

SAN DIEGO—At ACR Convergence 2023, Philip Seo, MD, MHS, presented an overview of clinical updates in rheumatology from the past year.

Filed under:ACR ConvergenceBiologics/DMARDsConditionsDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2023ankylosing spondylosisPolymyalgia Rheumatica

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences